FDAnews
www.fdanews.com/articles/75886-opi-and-the-uk-health-protection-agency-hpa-enter-into-a-world-wide-licensing-agreement-on-erwinase

OPI AND THE UK HEALTH PROTECTION AGENCY (HPA) ENTER INTO A WORLD-WIDE LICENSING AGREEMENT ON ERWINASE

August 30, 2005

OPi SA, Pharmaceuticals for Rare Diseases and the UK Health Protection Agency (HPA) announce today that they have entered into a world-wide licensing and supply agreement on Erwinase(R) (crisantaspase), L-asparaginase derived from Erwinia chrysanthemi. Erwinase(R) is indicated for the treatment of acute lymphoblastic leukaemia and may also be used in some other malignant hemopathies. Under the terms of the agreement, OPi is being granted worldwide exclusive rights to market the product, which is manufactured by the HPA in its recently upgraded Porton Down facility.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/08-30-2005/0004096132&EDATE=)